Outlook Therapeutics, Inc. (OTLK)
$0.56-5.08%Close
SELLCRISIS · day 12
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $23M
- Beta
- 0.75
- P/E (TTM)
- -0.25
- Short % float
- 118.41%
- Days to cover
- 7.1
- SI change
- -1.0%
- 1W
- -1.75%
- 1M
- -12.50%
- vs SPY 1W
- -1.62%
- vs SPY 1M
- -15.01%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 18
- VALUE
- 24
- GROWTH
- 65
- GARP
- 9
- TYPE
- Value / Recovery
Composite of Value · Growth · GARP
ROIC133.2%
REV YoY-
ROE222.0%
EPS YoY-
ROA-233.4%
GROSS196
OP4783
NET5255
[VALUATION]
P/E TTM-0.25
P/E FWD-
SECTOR PE20.48
INDUSTRY PE13.99
P/B-1.15
P/FCF-
EV/EBITDA-1.53
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E-
ALTMAN Z-
CURR RATIO0.81
ND/EBITDA-
BETA0.75
Company news
FAQ
- What is LOPJLB’s current signal on OTLK?
- LOPJLB’s latest quantitative signal on Outlook Therapeutics, Inc. (OTLK) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is OTLK in?
- Outlook Therapeutics, Inc. (OTLK) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Outlook Therapeutics, Inc. (OTLK) do?
- Outlook Therapeutics, Inc. is a biopharmaceutical company in the advanced stages of clinical development, focused on inventing and bringing to market monoclonal antibody treatments for various eye conditions. Its flagship drug candidate, ONS-5010, is an ophthalmic formulation of bevacizumab currently undergoing crucial Phase III clinical trials. This investigational product is being evaluated f…